Why randomization climbs the pyramid
The evidence hierarchy orders study designs by their ability to isolate causal relationships. Randomized controlled trials sit above observational designs because random assignment breaks the link between confounding variables and treatment. A person's socioeconomic status, genetics, or health literacy no longer predict who gets treated.
Below RCTs, cohort and case-control studies observe naturally occurring treatment groups, so unmeasured confounders bias the results. Case reports at the base describe single patients or small series without any comparison group, producing rich clinical detail but no causal signal.
When to trust lower tiers
The hierarchy assumes randomization is feasible and ethical. For rare outcomes or long-latency effects, a well-conducted case-control study beats a small, underpowered RCT. For new drugs, individual case reports accumulate safety signals years before large trials exist. The pyramid ranks design strength, not scientific value, acknowledging that the best available evidence sometimes sits lower than ideal.